Company news
Phio Pharmaceuticals Corp. news in 2020
Phio Pharmaceuticals Corp.'s news releases, calls and decks from 2020, newest first.
Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
November 9, 2020
Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment
November 8, 2020
Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 25, 2020
Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity
May 28, 2020
Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
May 11, 2020
Phio Pharmaceuticals Announces $4.0 Million Registered Direct Offering Priced At-the-Market
March 30, 2020
Phio Announces Positive New Data Validating the INTASYL™ Immunotherapy Platform's Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth
March 30, 2020
Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update
March 25, 2020
Phio Pharmaceuticals and Helmholtz Zentrum München Announce Collaboration and Option Agreement with Medigene
March 9, 2020
Phio Pharmaceuticals Announces Closing of $8.0 Million Underwritten Public Offering
February 12, 2020
Phio Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
February 10, 2020
Phio Pharmaceuticals Announces Compliance with Nasdaq Listing Requirements
February 9, 2020
Phio Pharmaceuticals Announces $1.74 Million Registered Direct Offering Priced At-the-Market
February 4, 2020